| Quarterly Financials | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 112 | 129 | 138 | 145 | 155 | 175 | 172 | 183 | 215 | 221 | 223 | 237 | 267 |
| Expenses | 85 | 94 | 102 | 105 | 113 | 126 | 120 | 131 | 158 | 163 | 164 | 175 | 193 |
| EBITDA | 26 | 34 | 37 | 39 | 42 | 49 | 52 | 52 | 57 | 58 | 59 | 62 | 74 |
| Operating Profit % | 23 % | 26 % | 26 % | 27 % | 27 % | 27 % | 28 % | 26 % | 25 % | 25 % | 25 % | 25 % | 25 % |
| Depreciation | 6 | 6 | 7 | 8 | 7 | 7 | 8 | 8 | 11 | 16 | 17 | 13 | 15 |
| Interest | 5 | 5 | 6 | 6 | 6 | 3 | 0 | 0 | 3 | 2 | 2 | 1 | 0 |
| Profit Before Tax | 16 | 23 | 24 | 25 | 29 | 40 | 44 | 44 | 43 | 40 | 40 | 49 | 59 |
| Tax | 5 | 7 | 3 | 8 | 10 | 12 | 14 | 6 | 13 | 9 | 10 | 10 | 17 |
| Net Profit | 11 | 16 | 21 | 17 | 19 | 28 | 30 | 38 | 30 | 31 | 31 | 39 | 42 |
| EPS in ₹ | 1.67 | 2.48 | 3.04 | 2.64 | 2.91 | 3.80 | 3.83 | 4.85 | 3.54 | 3.59 | 3.57 | 4.37 | 4.36 |
Yatharth Hospital
Yatharth Hospital
781.35
+0.35
(0.04%)
There are new updates from the company17 hours ago
View
Market Cap
7,528.60 Cr
EPS
14.72
PE Ratio
52.89
Dividend Yield
0.00 %
Industry
Healthcare Services52 Week High
819.95
52 Week Low
345.60
PB Ratio
4.69
Debt to Equity
0.04
Sector
Hospitals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
Company News
View All News
Yatharth Hospital and Trauma Care Services Limited's board approved the acquisition of 100% interest in Shantived Institute of Medical Sciences for an enterprise value of Rs. 260 crores. The target hospital is a 150-bed super specialty facility in Agra, Uttar Pradesh, expandable to 250 beds and spread across 1,65,000 square feet. The acquisition will be completed through cash consideration within 3 months and aims to expand Yatharth's presence and strengthen its positioning in the healthcare sector. The transaction is not a related party deal and requires no government or regulatory approvals.
Yatharth Hospital & Trauma Care Services achieved revenue of Rs. 2,578 million in Q1 FY26, marking 22% year-on-year growth and 11% quarter-over-quarter increase. Net profit surged 38% year-on-year to Rs. 420 million. The Greater Faridabad facility turned net profit positive within one year of operations, contributing Rs. 234 million in revenue (9% of total). EBITDA grew 20% year-on-year to Rs. 645 million with a 25% margin. The company inaugurated its New Delhi facility in July 2025 and plans to launch the Faridabad facility in late August 2025, adding ~700 beds combined. ARPOB increased 6% year-on-year to Rs. 32,395. Oncology now contributes 17% of Noida Extension's revenue and 10% of group revenue, showing 49% year-on-year growth. The company resolved the Jhansi land ownership issue and is transitioning to MSKA & Associates as statutory auditors. Management expects to maintain revenue growth around 30% and EBITDA margins similar to Q4 FY25 levels.
Yatharth Hospital & Trauma Care Services Limited submitted its monitoring agency report for the quarter ended June 30, 2025, detailing the utilization of Rs 6,039 million in net proceeds from its Qualified Institutional Placement (QIP). The company has utilized Rs 4,593.37 million of the total proceeds, with Rs 1,445.64 million remaining unutilized. Key utilizations include complete repayment of borrowings (Rs 956.80 million), hospital acquisition costs (Rs 2,163.17 million with Rs 10.68 million remaining), medical equipment purchases (Rs 400.56 million with Rs 1,116.80 million remaining), and general corporate purposes (Rs 1,072.83 million with Rs 318.16 million remaining). The monitoring agency Crisil Ratings Limited reported no deviations from the disclosed objects and confirmed all utilization was as per the offer document. The hospital at Model Town, Delhi was inaugurated on July 14, 2025. Unutilized funds are deployed in fixed deposits, mutual funds, and bank accounts earning returns between 5-6.4%.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,123.40 | #1 1,09,211.00 | 91.03 | 7,184.10 | #1 28.68 | 1,076 | 30.34 | 38.75 | |
7,510.00 | 1,07,982.30 | 68.57 | #1 21,994.30 | 14.76 | #1 1,505 | 39.78 | 42.87 | |
932.75 | 70,418.70 | 76.18 | 7,849.70 | 13.25 | 809 | #1 53.33 | 50.92 | |
1,725.00 | 35,252.20 | #1 44.56 | 5,575.00 | 12.29 | 790 | -2.38 | 39.23 | |
1,299.70 | 34,908.30 | 61.28 | 3,771.40 | 12.59 | 481 | 49.58 | 43.43 | |
625.10 | 32,387.70 | 90.59 | 4,286.70 | 15.12 | 337 | -98.18 | 58.09 | |
726.70 | 29,078.10 | 78.90 | 3,067.00 | 21.98 | 415 | -10.71 | 45.36 | |
1,361.80 | 13,829.30 | 53.71 | 1,566.90 | 17.46 | 244 | 35.52 | 24.06 | |
1,510.40 | 9,903.10 | 51.34 | 1,290.20 | 17.77 | 194 | -1.57 | 70.90 | |
647.40 | 9,025.80 | 244.98 | 2,257.70 | 17.03 | 49 | -55.88 | 46.29 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
30.68 %
Net Income Growth
13.97 %
Cash Flow Change
4,957.14 %
ROE
-39.11 %
ROCE
-37.63 %
EBITDA Margin (Avg.)
-7.47 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 193 | 257 | 287 | 309 | 426 | 486 | 1,019 | 1,731 |
| Fixed Assets | 54 | 164 | 190 | 251 | 303 | 299 | 442 | 605 |
| Current Assets | 28 | 24 | 29 | 49 | 109 | 176 | 510 | 856 |
| Capital Work in Progress | 110 | 65 | 62 | 0 | 0 | 0 | 0 | 222 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75 |
| Other Assets | 30 | 28 | 36 | 58 | 123 | 187 | 578 | 830 |
| Total Liabilities | 193 | 257 | 287 | 309 | 426 | 486 | 1,019 | 1,731 |
| Current Liabilities | 10 | 42 | 60 | 55 | 97 | 100 | 67 | 85 |
| Non Current Liabilities | 126 | 156 | 165 | 173 | 212 | 204 | 78 | 10 |
| Total Equity | 57 | 58 | 62 | 81 | 117 | 183 | 874 | 1,637 |
| Reserve & Surplus | 41 | 39 | 38 | 56 | 51 | 117 | 789 | 1,509 |
| Share Capital | 16 | 16 | 16 | 16 | 66 | 66 | 86 | 96 |
Cash Flow
| Cash Flow | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 1 | 9 | -13 | 1 | 3 | 7 | 26 | 75 | 249 |
| Investing Activities | -50 | -51 | -78 | -43 | -21 | -52 | -20 | -226 | -420 |
| Operating Activities | 25 | 17 | 18 | 39 | 44 | 60 | 64 | -3 | 150 |
| Financing Activities | 26 | 43 | 47 | 5 | -19 | -1 | -18 | 304 | 520 |
Share Holding
| % Holding | Mar 2022 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 96.91 % | 66.33 % | 66.33 % | 66.33 % | 66.44 % | 66.54 % | 66.54 % | 66.54 % | 61.44 % | 61.64 % | 61.64 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.99 % | 4.89 % | 6.28 % | 9.78 % | 4.45 % | 4.34 % |
| DIIs | 0.00 % | 9.07 % | 6.74 % | 8.88 % | 8.81 % | 9.33 % | 9.41 % | 6.98 % | 11.50 % | 13.56 % | 13.52 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 16.00 % | 16.00 % | 10.12 % | 12.82 % | 11.98 % | 12.11 % | 14.19 % | 11.83 % | 14.87 % | 15.29 % |
| Others | 3.09 % | 8.59 % | 10.93 % | 14.67 % | 11.92 % | 8.15 % | 7.04 % | 6.01 % | 5.45 % | 5.48 % | 5.21 % |
| No of Share Holders | 7 | 1,65,190 | 1,65,190 | 50,113 | 51,743 | 46,567 | 51,916 | 62,616 | 73,251 | 85,668 | 81,440 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Sept 2025 |  Annual General Meeting | NA | 30 Sept 2025 | 749.65 | 780.65 |
| 28 Sept 2024 | Annual General Meeting | NA | 28 Sept 2024 | 583.75 | 572.90 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 659.05 | 668.20 |
| 06 Dec 2024 |  Extraordinary General Meeting | NA | 06 Dec 2024 | 584.70 | 618.70 |
| 27 Jan 2025 | Quarterly Result Announcement | NA | 27 Jan 2025 | 438.45 | 442.90 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 506.70 | 523.00 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 627.80 | 650.80 |
Announcements
Closure of Trading Window
17 hours ago
17 hours agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 13, 2025
Sep 13, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 13, 2025
Sep 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 09, 2025
Sep 09, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 08, 2025
Sep 08, 2025Reg. 34 (1) Annual Report.Sep 08, 2025
Sep 08, 2025Notice Of 18Th Annual General Meeting Of The CompanySep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Meeting UpdatesSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 12, 2025
Aug 12, 2025Monitoring Agency Report For The Quarter Ended June 30 2025 - IPOAug 12, 2025
Aug 12, 2025Monitoring Agency Report For The Quarter Ended June 30 2025 - QIP.Aug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Resignation of Statutory AuditorsAug 05, 2025
Aug 05, 2025Appointment Of Secretarial Auditor & Cost AuditorAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2025
Aug 05, 2025Un-Audited Financial Results For The Quarter Ended June 30 2025.Aug 05, 2025
Aug 05, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. August 05 2025Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 01, 2025
Aug 01, 2025Board Meeting Intimation for Unaudited Financial Results For The First Quarter FY26Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Change in Corporate Office AddressJul 17, 2025
Jul 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 15, 2025
Jul 15, 2025Announcement Under Reg. 30 Part A Para B.Jul 14, 2025
Jul 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 14, 2025
Jul 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 03, 2025
Jul 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 03, 2025
Jul 03, 2025Resolution Of Ramraja Hospital Land DisputeJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 28, 2025
Jun 28, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 04, 2025
Jun 04, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2025
May 27, 2025Re-Appointment Of M/S Deloitte Touche Tohmatsu India LLP As Internal Auditor For The FY 2025-26.May 27, 2025
May 27, 2025Resignation Of Mr. Neeraj VinayakMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2025
May 26, 2025Audited Financial Results For The Q4 & FY25May 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 26, 2025
May 26, 2025Board Meeting Outcome for Audited Financial Result For Q4 & FY2025May 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 21, 2025
May 21, 2025Board Meeting Intimation for To Consider And Approve The Audited Financial Results (Standalone And Consolidated) Of The Company For The Fourth Quarter And Financial Year Ended March 31 2025.May 19, 2025
May 19, 2025Monitoring Agency Report For The Quarter Ended March 31 2025.May 15, 2025
May 15, 2025Monitoring Agency Report For The Quarter Ended March 31 2025.May 15, 2025
May 15, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 17, 2025
Apr 17, 2025Technical Indicators
RSI(14)
Neutral 59.18
ATR(14)
Less Volatile 26.08
STOCH(9,6)
Neutral 24.61
STOCH RSI(14)
Oversold 7.98
MACD(12,26)
Bearish -4.83
ADX(14)
Strong Trend 31.34
UO(9)
Bearish 35.14
ROC(12)
Downtrend And Accelerating -2.09
WillR(14)
Neutral -70.25
Mutual Fund Holdings
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
Bandhan Small Cap Fund Direct-Growth 
Kotak Balanced Advantage Fund Direct - Growth 
Taurus Mid Cap Fund Direct - Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
LIC MF Infrastructure Fund Direct-Growth 
HDFC Non-Cyclical Consumer Fund Direct - Growth 
ITI Pharma and Healthcare Fund Direct - Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
